Trial Profile
Phase Ib/2 trial for Gastrointestinal cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 29 Aug 2022
Price :
$35
*
At a glance
- Drugs Ompenaclid (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions
- 16 Oct 2018 New trial record
- 09 Oct 2018 According to Rgenix media release, company expects to lauch this study in 2018